Get the Stockscreener App
59.27
0.90%
0.53
After Hours:
59.25
-0.02
-0.03%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co Stock (BMY) Latest News
Glenmede Trust Co. NA Lowers Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Qsemble Capital Management LP Sells 12,253 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Loomis Sayles & Co. L P Has $14.36 Million Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Bristol Myers Sues HHS Over Rebate Model in Drug Discount Plan - Bloomberg Law
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Expanding access to lung cancer screening - Bristol Myers Squibb
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by D.A. Davidson & CO. - MarketBeat
Bristol Myers Squibb CEO to Present at Citi's 2024 Healthcare Conference | BMY Stock News - StockTitan
Eagle Asset Management Inc. Purchases Shares of 54,691 Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb stock boosted by CAR-T success and Camzyos ramp - Investing.com
Associated Banc Corp Sells 14,083 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Sompo Asset Management Co. Ltd. Has $2.58 Million Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Where Will Bristol Myers Squibb Be in 5 Years? - The Motley Fool
Meridian Wealth Management LLC Buys New Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback - Yahoo! Voices
Bristol-Myers Squibb: Expansion into Alzheimer's Disease Psychosis Treatment As A Key Growth Catalyst!Major Drivers - Smartkarma
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Charles Schwab Investment Management Inc. Has $3.16 Billion Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Integrated Investment Consultants LLC Invests $17.49 Million in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
John G Ullman & Associates Inc. Decreases Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Is Bristol Myers Squibb Stock a Buy? - The Motley Fool
Primecap Management Co. CA Cuts Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Commerce Bank Sells 30,241 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Buys New Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Vital Signs: Merck maps Keytruda's next act in the injectables marketplace - FirstWord Pharma
Psoriasis Market is expected to rise at a significant CAGR, DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb - Barchart
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Pzena Investment Management LLC Buys 67,409 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Advisors Asset Management Inc. Boosts Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Jennison Associates LLC - MarketBeat
Premier Fund Managers Ltd Takes Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
CAMZYOS™ Honoured with the Prix Galien Canada Innovative Product Award - Canada NewsWire
BRISTOL-MYERS SQUIBB CANADA WINS THE 2024 PRIX GALIEN INNOVATIVE PRODUCT AWARD - Barchart
J&J, Protagonist's oral psoriasis prospect scores in phase 3 pair, readying case against BMS' Sotyktu - Fierce Biotech
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by PNC Financial Services Group Inc. - MarketBeat
BMS CFO backs “resilient” pharma industry amid RFK’s impending governance - Pharmaceutical Technology
Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms - BioSpace
OneAscent Financial Services LLC Purchases Shares of 8,855 Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Bristol Myers Squibb is a Top 25 Dividend Giant (BMY) - Nasdaq
Bristol Myers to Present 90+ Studies at ASH, Including 5-Year Breyanzi Data | BMY Stock News - StockTitan
Aviance Capital Partners LLC Trims Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by MAI Capital Management - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Natixis Advisors LLC - MarketBeat
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases - AOL
Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer - Pharmaceutical Technology
Bristol-Myers Squibb: Buy This Bargain Stock Before It's Gone (NYSE:BMY) - Seeking Alpha
Swiss National Bank Boosts Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Kinsale Capital Group Inc. Purchases 18,163 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Mizuho Markets Americas LLC Lowers Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Kentucky Retirement Systems Lowers Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Wolfe Research Initiates Coverage of Bristol-Myers Squibb (BMY) with Peer Perform Recommendation - MSN
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol-Myers Squibb (NYSE:BMY) Trading Down 3%Here's Why - MarketBeat
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer - BioSpace
Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue - Benzinga
EU regulators endorse meds from BMS, J&J, Eisai and more—plus a clutch of biosims - FiercePharma
Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Sheaff Brock Investment Advisors LLC - MarketBeat
BMYBristol-Myers Squibb Co. Latest Stock News & Market Updates - StockTitan
Cornercap Investment Counsel Inc. Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Now Covered by Analysts at Wolfe Research - MarketBeat
Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments - BioSpace
Bristol Myers' Cancer Drug Repotrectinib Gains Key EU Panel Backing for Lung Cancer | BMY Stock News - StockTitan
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug - MSN
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):